Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 12, 2020
Daily News
October 12, 2020
- Make Temporary Measure Permitting Telemedicine Permanent: Reform Panel Members
October 12, 2020
- Take COVID as Opportunity to “Reset” Overdependence on Drug Price Cuts: PhRMA Chief
October 12, 2020
- Despite Price Cuts, Dupixent Netting Bullish Sales to Become Sanofi’s New Flagship
October 12, 2020
- MHLW to Reexamine Whether to Permit Sale of Emergency Contraceptives Without a Prescription
October 12, 2020
- Kissei Out-Licenses Parkinson’s Med to Hong Kong’s Affamed
October 12, 2020
- Canagliflozin Approved in Indonesia: Mitsubishi Tanabe
October 12, 2020
- Opdivo under PMDA Risk Review for Fulminant Hepatitis
October 12, 2020
- Takeda-Led Alliance Kicks Off Global PIII for COVID-19 Plasma Therapy
October 12, 2020
- Takeda, US Arrowhead Join Forces on Intractable Liver Disease Therapy
October 12, 2020
- Sumitomo Chemical, Sumitomo Dainippon Launch JV for Cell Therapy CDMO
October 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…